The 2026 obesity-drug coverage story sits across Medicare, Medicaid, private insurance, and employer-sponsored plans, with each tier moving at a different speed and through different mechanisms. The biggest single change is the Medicare GLP-1 Bridge demonstration, launched July 1, 2026 ($50/month copay for eligible Part D beneficiaries through Humana central processing, running through December 31, 2027), which represents the first time Medicare has helped pay for obesity-only-indication prescriptions since the Medicare Modernization Act language that has historically excluded them. Medicaid has moved the other way: Rhode Island stopped covering Wegovy, Zepbound, and Saxenda for weight loss on October 1, 2026, making it at least the seventh state Medicaid program to end or not renew obesity coverage in 2026.
Private-market coverage has reorganized faster. CVS Caremark added Lilly's Foundayo to formulary June 1 and reinstated Zepbound as preferred option October 1. Cigna and Express Scripts shifted toward step-therapy frameworks favoring orforglipron over injection-only options. Employer plans have moved unevenly: some large self-insured plans expanded obesity-drug coverage in 2026, others tightened prior-authorization criteria as utilization grew faster than projected. WTW's 2026 survey of 471 employers, released October 28, found weight-loss coverage fell from 57% to 53%, the first drop in three years, and 30% of employers still covering the drugs were considering dropping them. The compounded-GLP-1 channel that filled access gaps during the 2022-2024 shortages narrows in mid-2026 as the FDA finalizes 503B exclusion of semaglutide, tirzepatide, and liraglutide (comment window closed June 29).
The broader BALANCE Model, which lets payers cover GLP-1s at prices CMS negotiates with manufacturers, opened to state Medicaid programs in May 2026, but CMS says it will not launch in Medicare in 2027. Stories tagged here cover Medicare and Medicaid policy, private-payer formulary changes, prior-authorization mechanics, and the employer-sponsored coverage track. See #medicare-glp-1-bridge, #balance-model, #july-1-launch, and #cvs-caremark for adjacent threads.
After an hourslong debate on Thursday, November 5, the Milwaukee County Board of Supervisors rejected Supervisor Shawn Rolland's amendment to raise employee copays for GLP-1 drugs from $40 to $150 and, as WISN described it, offer them only to people with diabetes. Supervisor Sheldon Wasserman, a physician who supports the drugs' use, expects the county's cost to rise to as much as $15 million next year; Supervisor Deanna Alexander said the higher copay would have added $1,320 a year for patients following their doctors' plans.
WTW's 2026 Best Practices in Healthcare Survey of 471 U.S. employers with at least 100 workers found that 30% of those still covering the drugs are considering dropping them. Among employers that have dropped coverage or are weighing it, 91% cited cost. Employers project health costs to rise 11.1% in 2027 before plan changes and 9.7% after them.
As of Thursday, October 1, 2026, Rhode Island Medicaid no longer covers GLP-1 drugs such as Wegovy, Zepbound, and Saxenda when they are prescribed for weight loss, Rhode Island Current reported; the drugs remain covered for other conditions such as type 2 diabetes. The program paid for 24,971 GLP-1 prescriptions for obesity in fiscal year 2025, and state officials estimated the change would save $6.3 million in state general revenue and $20.3 million in combined state and federal funds. California, New Hampshire, Pennsylvania, South Carolina, Utah, and Massachusetts also ended or did not renew Medicaid obesity coverage this year.
The Centers for Medicare and Medicaid Services' Medicare GLP-1 Bridge demonstration program launched Wednesday July 1, 2026, opening prior-authorization submissions through Humana as central processor and activating the Bridge-specific pharmacy billing identifiers (BIN 028918, PCN MEDDGLP1BR). The program provides eligible Medicare Part D beneficiaries with $50/month access to four FDA-approved obesity drugs: Foundayo (orforglipron oral tablets, Eli Lilly), Wegovy injection (semaglutide, Novo Nordisk), Wegovy tablets (oral semaglutide in 1.5, 4, 9, and 25 mg strengths), and Zepbound KwikPen (tirzepatide single-dose autoinjector, Eli Lilly). CMS targets 72-hour prior-authorization turnaround. The Bridge runs through December 31, 2027 and transitions to the broader BALANCE Model launching January 2027 in Part D. It represents the first time Medicare has helped pay for drugs prescribed solely for obesity, breaking the 2003 Medicare Modernization Act exclusion that had barred obesity-only prescriptions from Part D coverage.
KFF (formerly Kaiser Family Foundation) published an analysis estimating 3.8 million Medicare beneficiaries could have qualified for the Medicare GLP-1 Bridge in 2023 based on the three BMI-and-comorbidity eligibility tiers (BMI ≥35 no paired condition; BMI ≥30 with heart failure, uncontrolled hypertension, or chronic kidney disease; BMI ≥27 with pre-diabetes, prior MI, prior stroke, or symptomatic peripheral artery disease). CMS Medicare Director Chris Klomp told reporters on the launch call that the agency expects participation to run in the 'single-digit millions' at first, with volume ramping through Q3 and Q4 2026 as prescriber and pharmacy familiarity grows. Centene confirmed participation in the Bridge program despite the parallel delay in its Medicare Advantage pilot. The Bridge operates outside standard Part D risk pools; Part D plan sponsors do not carry risk for eligible GLP-1 drugs under the Bridge. Net drug pricing runs $245/month with CMS covering $195 and the patient paying the $50 copay.
The Medicare GLP-1 Bridge demonstration program launches Wednesday July 1, 2026 (one day from this digest), providing eligible Medicare Part D beneficiaries with $50/month access to Foundayo (orforglipron), Wegovy (injection and 1.5/4/9/25 mg tablets), and Zepbound KwikPen through December 31, 2027. Operationally, Humana opens its central-processor function for prior-authorization submissions and claims adjudication starting tomorrow; the Bridge-specific pharmacy billing identifiers (BIN 028918, PCN MEDDGLP1BR) become active for first fills. Walgreens published pharmacist-navigation guidance Tuesday flagging that store pharmacists will help Medicare patients verify eligibility (the three-tier BMI-and-comorbidity criteria walked through in this site's June 29 patient-guide insight), confirm Part D enrollment status, and submit the Bridge prior-authorization request to Humana through the dedicated workflow. CNN published a June 29 consumer explainer flagging that the program is the first time Medicare has paid for drugs prescribed solely for obesity. The Bridge runs in parallel with the broader BALANCE Model launching January 2027 in Part D, with the Bridge ending December 31, 2027 and beneficiaries transitioning to BALANCE.
Mainstream-media coverage of the Medicare GLP-1 Bridge demonstration intensified through the weekend ahead of Wednesday's July 1 launch. The Washington Post published 'Medicare is about to cover GLP-1 drugs for weight loss. Here's what to know' on June 29; CBS News ran a parallel explainer the same day; CNBC's June 28 piece flagged that a large share of eligible seniors may not yet know about the coverage expansion. The shared message across the three outlets: the program is the first time Medicare will help pay for drugs prescribed solely for obesity (rather than for diabetes, cardiovascular risk, or another approved indication), the $50/month copay applies to Foundayo (orforglipron tablets), Wegovy (injection and 1.5/4/9/25 mg tablets), and Zepbound KwikPen, the demonstration runs through December 31, 2027, and Humana acts as the single central processor for prior authorization and claims adjudication. CMS estimates several hundred thousand Medicare Part D beneficiaries will qualify under the three-tier BMI eligibility framework (BMI ≥35; BMI ≥30 with comorbid heart failure, uncontrolled hypertension, or chronic kidney disease; BMI ≥27 with prediabetes, prior MI, prior stroke, or peripheral artery disease). The Bridge transitions to the broader BALANCE Model launching January 2027 in Medicare Part D.
The Centers for Medicare and Medicaid Services' GLP-1 Bridge demonstration launches Wednesday July 1, 2026 — 8 days from this digest's publication — providing eligible Medicare Part D beneficiaries with $50/month access to Foundayo (orforglipron), Wegovy injection, Wegovy pill, and Zepbound KwikPen for chronic weight management. The program runs through December 31, 2027 as a short-term bridge to the broader BALANCE Model (launching January 2027 in Medicare Part D). Humana, the current administrator of the Limited Income Newly Eligible Transition (LI NET) program, serves as the single central processor for prior authorization, claims adjudication, and pharmacy payment. CMS published the prior authorization fax form and prescriber/pharmacy educational materials on June 3, 2026. Eligibility requires BMI ≥30 (or ≥27 with comorbidities) and Part D enrollment. The launch arrives the same week as the Hims & Hers stock breakout and the FDA retatrutide compassionate-use disclosure — a coincidence that sharpens the peptide-access-equity debate as the broader US population continues to navigate $1,000+/month branded GLP-1 list prices.
The Business Group on Health's June 2026 survey of 105 large US employers found 67% currently cover GLP-1 drugs for weight management, but about 10% of those covering plan to drop coverage in 2027 as total spending continues to climb even as per-unit GLP-1 prices have fallen. The Foundayo and Wegovy pill launches drew in patients who had not previously tried GLP-1 therapy, increasing aggregate utilization. Employers that continue covering are layering on management strategies: required participation in a weight-management program, biometric eligibility verification, and restricted prescribing to specific providers. The 2027 employer-coverage cliff is the next financial pressure point for Lilly, Novo, and the pharmacy benefit managers that have built obesity formularies around employer-sponsored plans.